爱泼斯坦-巴尔病毒（EBV）编码的主要组织相容性复合体I类TAP抑制剂BNLF2a在EBV阳性胃癌中的潜伏表达
Latent Expression of the Epstein-Barr Virus (EBV)-Encoded Major Histocompatibility Complex Class I TAP Inhibitor, BNLF2a, in EBV-Positive Gastric Carcinomas.
作者信息
Strong Michael J, Laskow Thomas, Nakhoul Hani, Blanchard Eugene, Liu Yaozhong, Wang Xia, Baddoo Melody, Lin Zhen, Yin Qinyan, Flemington Erik K
机构信息
Department of Pathology, Tulane University Health Sciences Center, New Orleans, Louisiana, USA Tulane Cancer Center, New Orleans, Louisiana, USA.
Department of Microbiology, Immunology & Parasitology, Louisiana State University School of Medicine, New Orleans, Louisiana, USA.
出版信息
J Virol. 2015 Oct;89(19):10110-4. doi: 10.1128/JVI.01110-15. Epub 2015 Jul 15.
Abstract
The Epstein-Barr virus (EBV) BNLF2a gene product provides immune evasion properties to infected cells through inhibition of transporter associated with antigen processing (TAP)-mediated transport of antigen peptides. Although BNLF2a is considered to be a lytic gene, we demonstrate that it is expressed in nearly half of the EBV-associated gastric carcinomas analyzed. Further, we show that BNLF2a expression is dissociated from lytic gene expression. BNLF2a is therefore expressed in this latency setting, potentially helping protect the infected tumor cells from immunosurveillance.
摘要
爱泼斯坦-巴尔病毒（EBV）的BNLF2a基因产物通过抑制与抗原加工相关的转运体（TAP）介导的抗原肽转运，赋予受感染细胞免疫逃逸特性。尽管BNLF2a被认为是一个裂解基因，但我们证明在近一半分析的EBV相关胃癌中它是表达的。此外，我们表明BNLF2a的表达与裂解基因的表达无关。因此，BNLF2a在这种潜伏状态下表达，可能有助于保护受感染的肿瘤细胞免受免疫监视。
相似文献
1
Latent Expression of the Epstein-Barr Virus (EBV)-Encoded Major Histocompatibility Complex Class I TAP Inhibitor, BNLF2a, in EBV-Positive Gastric Carcinomas.
J Virol. 2015 Oct;89(19):10110-4. doi: 10.1128/JVI.01110-15. Epub 2015 Jul 15.
2
Stage-specific inhibition of MHC class I presentation by the Epstein-Barr virus BNLF2a protein during virus lytic cycle.
PLoS Pathog. 2009 Jun;5(6):e1000490. doi: 10.1371/journal.ppat.1000490. Epub 2009 Jun 26.
3
The EBV immunoevasins vIL-10 and BNLF2a protect newly infected B cells from immune recognition and elimination.
PLoS Pathog. 2012;8(5):e1002704. doi: 10.1371/journal.ppat.1002704. Epub 2012 May 17.
4
Epstein-Barr virus isolates retain their capacity to evade T cell immunity through BNLF2a despite extensive sequence variation.
J Virol. 2012 Jan;86(1):572-7. doi: 10.1128/JVI.05151-11. Epub 2011 Oct 19.
5
Sequence analysis of EBV immune evasion gene BNLF2a in EBV associated tumors and healthy individuals from nasopharyngeal carcinoma endemic and non-endemic regions of China.
J Med Virol. 2015 Nov;87(11):1946-52. doi: 10.1002/jmv.24254. Epub 2015 Jun 2.
6
EBV protein BNLF2a exploits host tail-anchored protein integration machinery to inhibit TAP.
J Immunol. 2011 Mar 15;186(6):3594-605. doi: 10.4049/jimmunol.1002656. Epub 2011 Feb 4.
7
Epstein-Barr viral BNLF2a protein hijacks the tail-anchored protein insertion machinery to block antigen processing by the transport complex TAP.
J Biol Chem. 2011 Dec 2;286(48):41402-41412. doi: 10.1074/jbc.M111.237784. Epub 2011 Oct 7.
8
Specific targeting of the EBV lytic phase protein BNLF2a to the transporter associated with antigen processing results in impairment of HLA class I-restricted antigen presentation.
J Immunol. 2009 Feb 15;182(4):2313-24. doi: 10.4049/jimmunol.0803218.
9
Epstein-Barr virus evasion of CD8(+) and CD4(+) T cell immunity via concerted actions of multiple gene products.
Semin Cancer Biol. 2008 Dec;18(6):397-408. doi: 10.1016/j.semcancer.2008.10.008. Epub 2008 Oct 25.
10
Impaired transporter associated with antigen processing-dependent peptide transport during productive EBV infection.
J Immunol. 2005 Jun 1;174(11):6829-38. doi: 10.4049/jimmunol.174.11.6829.
引用本文的文献
1
Viruses in glioblastoma: an update on evidence and clinical trials.
BJC Rep. 2024 Apr 19;2(1):33. doi: 10.1038/s44276-024-00051-z.
2
Epstein-Barr virus: the molecular virology and the associated diseases.
Fujita Med J. 2023 May;9(2):65-72. doi: 10.20407/fmj.2022-018. Epub 2022 Oct 28.
3
Functional Implications of Epstein-Barr Virus Lytic Genes in Carcinogenesis.
Cancers (Basel). 2022 Nov 24;14(23):5780. doi: 10.3390/cancers14235780.
4
Rta is the principal activator of Epstein-Barr virus epithelial lytic transcription.
PLoS Pathog. 2022 Sep 29;18(9):e1010886. doi: 10.1371/journal.ppat.1010886. eCollection 2022 Sep.
5
Viral and cellular oncogenes promote immune evasion.
Oncogene. 2022 Feb;41(7):921-929. doi: 10.1038/s41388-021-02145-1. Epub 2022 Jan 13.
6
Whole-genome profiling of nasopharyngeal carcinoma reveals viral-host co-operation in inflammatory NF-κB activation and immune escape.
Nat Commun. 2021 Jul 7;12(1):4193. doi: 10.1038/s41467-021-24348-6.
7
Pathogenic Role of Epstein-Barr Virus in Lung Cancers.
Viruses. 2021 May 11;13(5):877. doi: 10.3390/v13050877.
8
Comprehensive Epstein-Barr Virus Transcriptome by RNA-Sequencing in Angioimmunoblastic T Cell Lymphoma (AITL) and Other Lymphomas.
Cancers (Basel). 2021 Feb 4;13(4):610. doi: 10.3390/cancers13040610.
9
Essential Genes to Consider in Epstein-Barr Virus-Associated Gastric Cancer: A Systematic Review.
Cureus. 2020 Nov 21;12(11):e11610. doi: 10.7759/cureus.11610.
10
High Levels of Class I Major Histocompatibility Complex mRNA Are Present in Epstein-Barr Virus-Associated Gastric Adenocarcinomas.
Cells. 2020 Feb 21;9(2):499. doi: 10.3390/cells9020499.
本文引用的文献
1
High-throughput RNA sequencing-based virome analysis of 50 lymphoma cell lines from the Cancer Cell Line Encyclopedia project.
J Virol. 2015 Jan;89(1):713-29. doi: 10.1128/JVI.02570-14. Epub 2014 Oct 29.
2
Comprehensive molecular characterization of gastric adenocarcinoma.
Nature. 2014 Sep 11;513(7517):202-9. doi: 10.1038/nature13480. Epub 2014 Jul 23.
3
Comprehensive high-throughput RNA sequencing analysis reveals contamination of multiple nasopharyngeal carcinoma cell lines with HeLa cell genomes.
J Virol. 2014 Sep;88(18):10696-704. doi: 10.1128/JVI.01457-14. Epub 2014 Jul 2.
4
Differences in gastric carcinoma microenvironment stratify according to EBV infection intensity: implications for possible immune adjuvant therapy.
PLoS Pathog. 2013;9(5):e1003341. doi: 10.1371/journal.ppat.1003341. Epub 2013 May 9.
5
Characterization of naturally Epstein-Barr virus-infected gastric carcinoma cell line YCCEL1.
J Gen Virol. 2013 Mar;94(Pt 3):497-506. doi: 10.1099/vir.0.045237-0. Epub 2012 Nov 21.
6
Whole-genome sequencing of the Akata and Mutu Epstein-Barr virus strains.
J Virol. 2013 Jan;87(2):1172-82. doi: 10.1128/JVI.02517-12. Epub 2012 Nov 14.
7
STAR: ultrafast universal RNA-seq aligner.
Bioinformatics. 2013 Jan 1;29(1):15-21. doi: 10.1093/bioinformatics/bts635. Epub 2012 Oct 25.
8
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature. 2012 Mar 28;483(7391):603-7. doi: 10.1038/nature11003.
9
Establishment and characterization of six human gastric carcinoma cell lines, including one naturally infected with Epstein-Barr virus.
Cell Oncol (Dordr). 2012 Apr;35(2):127-36. doi: 10.1007/s13402-012-0073-9. Epub 2012 Feb 24.
10
Detection of murine leukemia virus in the Epstein-Barr virus-positive human B-cell line JY, using a computational RNA-Seq-based exogenous agent detection pipeline, PARSES.
J Virol. 2012 Mar;86(6):2970-7. doi: 10.1128/JVI.06717-11. Epub 2012 Jan 11.
Zotero 插件